The Transgenic Mouse Shared Resource is a fully Cancer Center-managed facility. The generation and use of transgenic and gene-targeted mice is an essential technology for basic cancer research. Since its establishment in 1995 the Transgenic Mouse Shared Resource has served to make transgenic technologies accessible to all Cancer Center members, which has had a major impact on the quality and quantity of cancer research using genetically modified mouse models. The resource has served over 80 different investigators over the past three years, and has generated hundreds of new strains of transgenic and gene-targeted mice. The services provided by the Transgenic Mouse Shared Resource are: ? Production of transgenic mice by pronuclear DMA microinjection and embryo transfer; ? Production of chimeric mice by blastocyst injection of genetically modified ES cells and embryo transfer, which is part of the procedure of producing knockout or knockin mice;and ? Gene targeting, which involves the electroporation of a targeting vector into pluripotent mouse embryonic stem (ES) cells and the selection of gene-targeted clones; ? Education of investigators and advice on vector and experimental design for experiments using transgenic and knockout mice. The facility maintains a library of vectors and genes that are generally useful for the construction of transgenes and targeting vectors. In the future, to supplement these now standard transgenic methods, we plan to establish a service that will use """"""""BAG recombineering"""""""" to efficiently produce large-insert gene targeting vectors and transgenes. Beyond these specific fee-based services, the Resource provides free advice and consultation on all aspects of the design, generation, breeding and analysis of genetically modified mouse models. The Director (Dr. Frank Costantini), Co-Director (Dr. Thomas Ludwig) and Manager (Dr. Chyuan-Sheng Lin) of the facility collectively have many decades of experience in numerous aspects of mouse genetics, transgenic mo'use technology, and the use of mouse models in cancer research, and their expertise has contributed greatly to the excellence of transgenic mouse research at Columbia. During the last period of the CCSG, 51% of the investigators using the facility were Cancer Center members with peer-reviewed funding, with those members representing from 53% to 78% of the usage of the 3 available services. The proposed total operating budget of the facility is $531,018 for the Transgenic Mouse Shared Resource, of which we are requesting $183,948 from the CGSG. In addition, mouse cage costs managed by the Institute for Comparative Medicine are $324,111, of which we are requesting $135,771 from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013696-36
Application #
7862547
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
36
Fiscal Year
2009
Total Cost
$461,783
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677
Bianchetti, E; Bates, S J; Carroll, S L et al. (2018) Usp9X Regulates Cell Death in Malignant Peripheral Nerve Sheath Tumors. Sci Rep 8:17390
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Shang, Enyuan; Zhang, Yiru; Shu, Chang et al. (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8:15383
Shen, Megan Johnson; Prigerson, Holly G; Ratshikana-Moloko, Mpho et al. (2018) Illness Understanding and End-of-Life Care Communication and Preferences for Patients With Advanced Cancer in South Africa. J Glob Oncol :1-9
Apatoff, Mary Ben L; Sengillo, Jesse D; White, Eugenia C et al. (2018) Autologous stem cell therapy for inherited and acquired retinal disease. Regen Med 13:89-96
Billing, David; Horiguchi, Michiko; Wu-Baer, Foon et al. (2018) The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection. Mol Cell 72:127-139.e8
Connors, Thomas J; Baird, J Scott; Yopes, Margot C et al. (2018) Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection. J Immunol 201:432-439

Showing the most recent 10 out of 331 publications